Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia

Immunotherapy
Willemijn van den AnckerArjan A van de Loosdrecht

Abstract

Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumor responses. For instance, monocyte-derived DCs have been loaded with apoptotic whole-cell suspensions, necrotic cell lysates, tumor-associated peptides, eluted peptides and cellular DNA or RNA. Furthermore, monocyte-derived DCs can be chemically or electrically fused with leukemic blasts, and DCs have been cultured out of leukemic blasts. However, it remains a challenge in cancer immunotherapy to identify which of these methods is the most optimal for antigen loading and activation of DCs. This review discusses recent advances in DC research and the application of this knowledge towards new strategies for antigen loading of DCs in the treatment of minimal residual disease in acute myeloid leukemia.

References

Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·R E ToesW M Kast
Jun 22, 1999·Leukemia Research·M A RoskrowM K Brenner
Feb 9, 2000·The Journal of Experimental Medicine·R M SteinmanK Inaba
Sep 16, 2000·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·H HasebeM Eriguchi
Dec 20, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·W J MagnerT B Tomasi
Mar 10, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·L FongE G Engleman
Sep 8, 2001·Nature Immunology·M SchnareR Medzhitov
Jan 10, 2002·The Journal of Experimental Medicine·Sebastian Amigorena
May 11, 2002·Nature Reviews. Immunology·Drew M Pardoll
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Jan 28, 2003·Cancer·Denis R Clohisy, Patrick W Mantyh
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Isabelle BedrosianBrian J Czerniecki
Dec 30, 2003·International Journal of Cancer. Journal International Du Cancer·Jochen GreinerMichael Schmitt
Jan 23, 2004·Cancer Investigation·Derry Ridgway
Apr 2, 2004·Nature Reviews. Immunology·Dennis M Klinman
May 4, 2004·Nature Medicine·Carl G FigdorCornelis J M Melief
Aug 3, 2004·Nature Reviews. Immunology·Jukka Vakkila, Michael T Lotze
Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo
Sep 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yoshihiro OkaHaruo Sugiyama
Feb 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Samudra K DissanayakeSuzanne Ostrand-Rosenberg
Apr 2, 2005·Nature Reviews. Immunology·Jacques Banchereau, A Karolina Palucka
May 27, 2005·Cancer Immunology, Immunotherapy : CII·Lorenz HöltlMartin Thurnher

❮ Previous
Next ❯

Citations

Dec 3, 2011·Clinical Reviews in Allergy & Immunology·Syh-Jae LinMing-Ling Kuo
Aug 2, 2013·Immunotherapy·Jurjen M RubenArjan A van de Loosdrecht
Nov 15, 2012·Immunotherapy·Robin CornelissenJoachim G Aerts
Jan 5, 2014·Cancer Immunology, Immunotherapy : CII·Jurjen M RubenArjan A van de Loosdrecht
Jul 22, 2011·Stem Cells International·Marta Isabel Pereira, Artur Paiva
Jun 13, 2012·Cytotherapy·Sébastien AnguilleZwi N Berneman
Jan 28, 2015·Human Vaccines & Immunotherapeutics·Athalia R PyzerJacalyn Rosenblatt
Aug 5, 2015·Pharmacological Reviews·Sébastien AnguilleZwi N Berneman
Oct 23, 2015·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Yan BaiDong-Feng Zhou

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM-CSF

Methods Mentioned

BETA
MDS
chromosomal
PCR
flow cytometry

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.